UNSPSC 51142418: Donitriptan

This classification denotes a serotonin agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 70968BVH2J. European Medicines Agency schedules Donitriptan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01817MIG. Donitriptan generally arises in the molecular formula C23H25N5O2. The term DONITRIPTAN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, no. 3, 2000, list 44.) Most nations schedule donitriptan under HS 29335995 and SITC 51576.

As of Q4 2014, DONITRIPTAN remains the US FDA Preferred Term for this commodity. Donitriptan bears US NLM identifiers UMLS ID C0769585 and NCI Concept Code C65466. SMILES: O(CC(=O)N1CCN(CC1)C1CCC(CC1)C#N)C1CC2C(CCN)C[NH]C2CC1.

UNSPSC 51142418 Donitriptan is a Commodity code, but the recent state and local contract opportunities tagged under it do not reflect donitriptan procurement — instead, they show health agencies purchasing naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products through competitive bidding and cooperative purchasing frameworks. The three most recent opportunities reveal that state and local governments use this code area (or related pharmaceutical commodity codes) to solicit finished pharmaceutical products, injectable medications, and complementary health-support items through IFB, RFP, and RFI notice types, with suppliers required to maintain FDA compliance, cGMP certification, Drug Supply Chain Security Act (DSCSA) compliance, and specific insurance coverages. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance / MMCAP), indicating a mix of local health systems and state-level procurement vehicles that aggregate demand across multiple jurisdictions.

Geographic activity spans Florida, Texas, Minnesota, and Oregon, with the MMCAP cooperative vehicle serving multiple states and the Texas HHS Commission undertaking exploratory market research for a direct-to-manufacturer pharmacy program. Representative recent opportunities include Seminole County's IFB60459723LAS (posted June 30, 2026; due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) seeking vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program; and the MMCAP RFP S1070000015802 (posted January 20, 2026; due March 26, 2026) for generic pharmaceuticals and OTC products with awards effective July 1, 2026. The code shows inconsistent tagging — the nominal commodity (donitriptan, a migraine treatment) does not appear in any of the three recent opportunities, suggesting either a cataloging misalignment or that this specific drug formulation sees minimal recent state and local procurement activity.